Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 14/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805968 | 0.83 | CA1 (0.49) | LIPE | |
| SCHEMBL14746564 | 0.83 | LPL (0.53) | LIPE | |
| SCHEMBL15383840 | 0.81 | KDM4E (0.44) | LIPERAB9A | |
| SCHEMBL14743896 | 0.81 | NPC1 (0.47) | LIPERAB9A | |
| SCHEMBL19019672 | 0.80 | KDM4E (0.54) | LIPERAB9A | |
| SCHEMBL14165741 | 0.80 | LPL (0.53) | LIPE | |
| SCHEMBL14746622 | 0.80 | LIPE (0.46) | LIPE | |
| SCHEMBL11351938 | 0.80 | MAPT (0.69) | LIPEMAPTNPSR1LMNARAB9A | |
| SCHEMBL31491396 | 0.77 | DGAT1 (0.47) | LIPE | |
| SCHEMBL5784394 | 0.77 | DGAT1 (0.52) | LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083606-B1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10000475-B2 | Triazine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9765029-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765029-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9745287-B2 | Pyrimidines and use thereof | PURDUE PHARMA L.P. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9637458-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. | 2017-05-02 | — | — | US | disclosed |
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. | 2016-11-17 | — | — | US | disclosed |
| US-20160009659-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2016-01-14 | — | — | US | disclosed |
| US-20150353512-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-12-10 | — | — | US | disclosed |
| US-20150344465-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-12-03 | — | — | US | disclosed |
| US-20150344465-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-12-03 | — | — | US | disclosed |
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-09-17 | — | — | US | disclosed |
| US-9120752-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120752-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120786-B2 | Triazine carboxamides as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-09-01 | — | — | US | disclosed |
| WO-2015094443-A1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-9056832-B2 | Pyridine compounds and the users thereof | PURDUE PHARMA L.P. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20140249128-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012035421-A2 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249128-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, SCN2A, SCN2B | LIPE 2804/4885MAPT 3332/4885NPSR1 129/4885 |
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, CACNA1A, KCNA1 | LIPE 4063/4885MAPT 3114/4885NPSR1 99/4885 |
| US-20150353512-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, SCN2A, SCN2B | LIPE 2804/4885MAPT 3332/4885NPSR1 129/4885 |
| US-10000475-B2 | Triazine carboxamides as sodium channel blockers | TRPV1, SCN2A, SCN2B | LIPE 2804/4885MAPT 3332/4885NPSR1 129/4885 |
| US-20160009659-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | CACNA1A, TRPV1, TRPA1 | LIPE 3898/4885MAPT 3982/4885NPSR1 179/4885 |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | TRPV1, CACNA1A, KCNA1 | LIPE 4063/4885MAPT 3114/4885NPSR1 99/4885 |
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | ADORA2B, P2RX2, P2RX3 | LIPE 4338/4885MAPT 3583/4885NPSR1 148/4885 |
| US-20150344465-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SCN1B, CACNA1A, SCN1A | LIPE 4468/4885MAPT 2389/4885NPSR1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.